229 related articles for article (PubMed ID: 19665499)
41. Vigilance states in a parkinsonian model, the MPTP mouse.
Monaca C; Laloux C; Jacquesson JM; Gelé P; Maréchal X; Bordet R; Destée A; Derambure P
Eur J Neurosci; 2004 Nov; 20(9):2474-8. PubMed ID: 15525288
[TBL] [Abstract][Full Text] [Related]
42. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
43. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
44. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
45. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Rolland AS; Tandé D; Herrero MT; Luquin MR; Vazquez-Claverie M; Karachi C; Hirsch EC; François C
J Neurochem; 2009 Aug; 110(4):1321-9. PubMed ID: 19527435
[TBL] [Abstract][Full Text] [Related]
46. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
[TBL] [Abstract][Full Text] [Related]
47. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
48. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
[TBL] [Abstract][Full Text] [Related]
49. Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.
Cano-Jaimez M; Pérez-Sánchez F; Milán M; Buendía P; Ambrosio S; Fariñas I
Neurobiol Dis; 2010 Apr; 38(1):92-103. PubMed ID: 20079841
[TBL] [Abstract][Full Text] [Related]
50. Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Lin JW; Shih CM; Chen YC; Lin CM; Tsai JT; Chiang YH; Shih R; Chiu PL; Hung KS; Yeh YS; Wei L; Chiu WT; Yang LY
Surg Neurol; 2009 Dec; 72 Suppl 2():S55-65; discussion S65. PubMed ID: 19944827
[TBL] [Abstract][Full Text] [Related]
51. Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.
Choudhury ME; Moritoyo T; Kubo M; Kyaw WT; Yabe H; Nishikawa N; Nagai M; Matsuda S; Nomoto M
Brain Res; 2011 Apr; 1384():170-8. PubMed ID: 21320474
[TBL] [Abstract][Full Text] [Related]
52. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
[TBL] [Abstract][Full Text] [Related]
53. Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease.
Goldberg NR; Haack AK; Meshul CK
Neuroscience; 2011 Jan; 172():443-52. PubMed ID: 20933577
[TBL] [Abstract][Full Text] [Related]
54. MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut.
Natale G; Kastsiushenka O; Fulceri F; Ruggieri S; Paparelli A; Fornai F
Brain Res; 2010 Oct; 1355():195-206. PubMed ID: 20691673
[TBL] [Abstract][Full Text] [Related]
55. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
Szego ÉM; Gerhardt E; Kermer P; Schulz JB
Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
[TBL] [Abstract][Full Text] [Related]
56. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
[TBL] [Abstract][Full Text] [Related]
57. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
[TBL] [Abstract][Full Text] [Related]
58. [Optimization of counting process of dopaminergic neurons in substantia nigra of parkinsonian mice].
Khaindrava VG; Ershov PV; Antsiperov VE; Obukhov IuV; Nanaev AK; Ugriumov MV
Tsitologiia; 2010; 52(6):423-30. PubMed ID: 20737900
[TBL] [Abstract][Full Text] [Related]
59. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.
Ugrumov MV; Khaindrava VG; Kozina EA; Kucheryanu VG; Bocharov EV; Kryzhanovsky GN; Kudrin VS; Narkevich VB; Klodt PM; Rayevsky KS; Pronina TS
Neuroscience; 2011 May; 181():175-88. PubMed ID: 21382448
[TBL] [Abstract][Full Text] [Related]
60. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease.
Peoples C; Spana S; Ashkan K; Benabid AL; Stone J; Baker GE; Mitrofanis J
Parkinsonism Relat Disord; 2012 Jun; 18(5):469-76. PubMed ID: 22285756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
